English

Our group

Thallion and LFB complete patient enrollment of Phase II Shigatec trial

09/01/2012

LFB Announces U.S. Patent on Monoclonal Antibodies with Enhanced Activity

08/07/2011

The Prix Galien was awarded to LFB in the "Medicine for the Treatment of Rare Diseases" category

25/05/2011

Thallion announces first patient enrolled in high dose cohort of phase II Shigatec trial

30/05/2011

GTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent

19/05/2011

THALLION AND LFB INITIATE PHASE II SHIGATEC TRIAL

29/11/2010

LFB's recombinant anti-CD20 monoclonal antibody is granted orphan drug status in the USA for Chronic Lymphocytic Leukemia

06/08/2010

LFB Launches Process to buy out Austrian Plasma Collection Group to support its International Activity

22/06/2010

Sanofi-aventis and LFB industrial cooperation project in bio-production in France comes to fruition

22/04/2010

THALLION Pharmaceuticals and LFB BIOTECHNOLOGIES sign definitive agreement to develop and commercialize treatment for E.Coli infection

16/02/2010

FDA grants Orphan Drug Designation to LFB’s « Complement Factor H »

09/02/2010

Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments

02/02/2010

LFB’s recombinant anti-CD20 monoclonal antibody is granted orphan drug status in Europe for Chronic Lymphocytic Leukemia

25/11/2009

Sanofi-aventis and LFB announce an industrial cooperation project for bioproduction in France

28/10/2009

MAbgène expands its GMP facilities to produce phase III clinical and commercial batches of biomolecules

14/10/2009

GTC Biotherapeutics announces changes in board

01/10/2009

Hopes for prophylaxis and therapy for Chikungunya

28/09/2009

"Le Rire Médecin" in Brazil with LFB's support

25/08/2009

Francis Mer Joins the Board of Directors of LFB S.A.

29/07/2009

GTC Biotherapeutics enters agreements with LFB for funding of $12.3 million with an option for LFB to fund an additional $6.4 million

18/06/2009

Recall of medicinal product batches following a case of the classic form of Creutzfeldt-Jakob Disease (sporadic CJD) in a French blood donor

12/06/2009

A resounding “Thank you for the gift of life!” to French blood donors from the patients of the IRIS association supported by LFB

11/06/2009

Securization of Plasma-Derived Medicinal Products

19/02/2009

Therapure Biopharma Inc. and LFB Biotechnologies announce a development services contract for a new therapeutic protein

18/02/2009

First in man injections of LFB's first two therapeutic monoclonal antibodies

10/02/2009

<< Back